AIM
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- AIM ImmunoTech highlights growing interest in its Ampligen pancreatic cancer strategy as the Phase 2 DURIPANC trial advances toward topline resultsOct 1, 2026
- AIM ImmunoTech highlights Ampligen's potential role in pancreatic cancer treatment following FDA approval of daraxonrasibSep 22, 2026
- AIM ImmunoTech secured a broad U.S. patent for rintatolimod in combination with pembrolizumab, extending Ampligen oncology IP protection through 2039Aug 31, 2026
- AIM ImmunoTech reported positive interim Phase 2 data for Ampligen plus Imfinzi in pancreatic cancerJun 8, 2026
- AIM ImmunoTech highlighted entry into a pivotal phase with a planned Phase 3 Ampligen study in pancreatic cancerApr 17, 2026